PubMed:33754144 / 1713-1915 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/33754144","sourcedb":"PubMed","sourceid":"33754144","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/33754144","text":"At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76).","tracks":[{"project":"Inflammaging","denotations":[{"id":"T17","span":{"begin":0,"end":202},"obj":"Sentence"},{"id":"T17","span":{"begin":0,"end":202},"obj":"Sentence"}],"attributes":[{"subj":"T17","pred":"source","obj":"Inflammaging"},{"subj":"T17","pred":"source","obj":"Inflammaging"}]},{"project":"yangbin123xm_800_3","denotations":[{"id":"T8","span":{"begin":36,"end":48},"obj":"CI"},{"id":"T13","span":{"begin":143,"end":150},"obj":"CI"}],"attributes":[{"subj":"T8","pred":"source","obj":"yangbin123xm_800_3"},{"subj":"T13","pred":"source","obj":"yangbin123xm_800_3"}]},{"project":"chenxin_473849_800_3","denotations":[{"id":"T14","span":{"begin":143,"end":150},"obj":"CI"},{"id":"T9","span":{"begin":36,"end":48},"obj":"CI"}],"attributes":[{"subj":"T14","pred":"source","obj":"chenxin_473849_800_3"},{"subj":"T9","pred":"source","obj":"chenxin_473849_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Inflammaging","color":"#ec93c4","default":true},{"id":"yangbin123xm_800_3","color":"#93deec"},{"id":"chenxin_473849_800_3","color":"#ece093"}]}]}}